DISCLAIMER: This page is intended for members of the general public in Singapore only.
The information provided on this site is intended for general information and education for Singapore-based members of the public and is not intended to be a substitute for the advice provided by a physician or other qualified healthcare professional.
Information about the NuvaxovidTM dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted)
The Health Sciences Authority (HSA) of Singapore has authorized the interim authorization of the NuvaxovidTM COVID-19 Vaccine (recombinant, adjuvanted) under Regulations 60A(4) and (5)b of the Health Product (Therapeutic Products) Regulations, for use and supply as directed by the Government of Singapore. Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.
Important information
Report an Adverse Event (AE)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of Singapore: https://www.hsa.gov.sg/adverse-events.
Contact Us
Tel: +65 8003211411
09:00 - 17:00
Monday - Friday